Literature DB >> 32205591

Hyperferritinemia in Critically Ill Patients.

Gunnar Lachmann1,2, Cornelia Knaak1, Gerald Vorderwülbecke1, Paul La Rosée3, Felix Balzer1, Thomas Schenk4, Friederike S Schuster1, Peter Nyvlt1, Gritta Janka5, Frank M Brunkhorst6, Didier Keh1, Claudia Spies1.   

Abstract

OBJECTIVE: Hyperferritinemia is frequently seen in critically ill patients. A rather rare though life-threatening condition related to severely elevated ferritin is hemophagocytic lymphohistiocytosis. We analyze ferritin levels to differentiate hemophagocytic lymphohistiocytosis from other causes of hyperferritinemia in a mixed cohort of critically ill patients.
DESIGN: Retrospective observational study.
SETTING: Adult surgical, anesthesiologic, and medical ICUs of a university hospital. PATIENTS: Critical care patients (≥ 18 yr old) admitted to any of the adult ICUs at Charité - Universitätsmedizin Berlin between January 2006 and August 2018 with at least one ferritin value and hyperferritinemia (≥ 500 µg/L).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Patients were categorized into hemophagocytic lymphohistiocytosis, sepsis, septic shock, and other diagnoses. These were further categorized into 17 subgroups. Hemophagocytic lymphohistiocytosis diagnosis was based on Hemophagocytic Lymphohistiocytosis-2004 criteria and the HScore. Of 2,623 patients with hyperferritinemia, 40 were considered to have hemophagocytic lymphohistiocytosis (1.52%). Maximum ferritin levels were highest in hemophagocytic lymphohistiocytosis patients compared with all other disease groups (each p < 0.001). Sepsis and septic shock patients had higher maximum ferritin levels than patients with other diagnoses (each p < 0.001). A maximum ferritin value of 9,083 µg/L was at 92.5% sensitivity and 91.9% specificity for hemophagocytic lymphohistiocytosis (area under the curve, 0.963; 95% CI, 0.949-0.978). Of all subgroups with other diagnoses, maximum ferritin levels were highest in patients with varicella-zoster virus, hepatitis, or malaria (median, 1,935, 1,928, and 1,587 µg/L, respectively). Maximum ferritin levels were associated with increased in-hospital mortality (odds ratio, 1.518 per log µg/L [95% CI, 1.384-1.665 per log µg/L]; p < 0.001).
CONCLUSIONS: This is the largest study of patients with ferritin available in a mixed ICU cohort. Ferritin levels in patients with hemophagocytic lymphohistiocytosis, sepsis, septic shock, and other conditions were distinctly different, with the highest ferritin levels observed in hemophagocytic lymphohistiocytosis patients. Maximum ferritin of 9,083 µg/L showed high sensitivity and specificity and, therefore, may contribute to improved diagnosis of hemophagocytic lymphohistiocytosis in ICU. The inclusion of ferritin into the sepsis laboratory panel is warranted.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32205591     DOI: 10.1097/CCM.0000000000004131

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

1.  Analysis of the occurrence of hemophagocytic lymphohistiocytosis (HLH) features in patients with sepsis: a prospective study.

Authors:  Dominik Bursa; Agnieszka Bednarska; Andrzej Pihowicz; Marcin Paciorek; Andrzej Horban
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

2.  Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore.

Authors:  Cornelia Knaak; Peter Nyvlt; Friederike S Schuster; Claudia Spies; Patrick Heeren; Thomas Schenk; Felix Balzer; Paul La Rosée; Gritta Janka; Frank M Brunkhorst; Didier Keh; Gunnar Lachmann
Journal:  Crit Care       Date:  2020-05-24       Impact factor: 9.097

3.  Sustained Immunoparalysis in Endotoxin-Tolerized Monocytic Cells.

Authors:  Christina K Weisheit; Alexandra Klüners; Lennart Wild; Alexandra Casalter; Stefanie Heilmann-Heimbach; Sugirthan Sivalingam; Jan L Kleiner; Stefan F Ehrentraut; Andreas Hoeft; Stilla Frede; Heidi Ehrentraut
Journal:  Mediators Inflamm       Date:  2020-06-13       Impact factor: 4.711

Review 4.  COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.

Authors:  Carlo Perricone; Elena Bartoloni; Roberto Bursi; Giacomo Cafaro; Giacomo Maria Guidelli; Yehuda Shoenfeld; Roberto Gerli
Journal:  Immunol Res       Date:  2020-08       Impact factor: 2.829

Review 5.  [Hemophagocytic lymphohistiocytosis in critically ill patients].

Authors:  D A Eichenauer; G Lachmann; P La Rosée
Journal:  Med Klin Intensivmed Notfmed       Date:  2021-02-12       Impact factor: 1.552

6.  A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy.

Authors:  Hidenori Takahashi; Tomohiro Koiwa; Akira Fujita; Takayuki Suzuki; Amane Tagashira; Yoshinobu Iwasaki
Journal:  Respir Med Case Rep       Date:  2020-05-19

7.  [Interdisciplinary COVID board for patients with SARS-CoV-2-triggered hyperferritinemic Inflammation].

Authors:  P La Rosée; H-C Bremer; F La Rosée; P Mohm; A Hochhaus; I Gehrke; B Kumle; A Benzing; S Russo
Journal:  Med Klin Intensivmed Notfmed       Date:  2020-10-28       Impact factor: 0.840

8.  Plasma Levels of Mid-Regional Proadrenomedullin Accurately Identify H1N1pdm09 Influenza Virus Patients with Risk of Intensive Care Admission and Mortality in the Emergency Department.

Authors:  Blanca Valenzuela-Méndez; Francisco Valenzuela-Sánchez; Juan Francisco Rodríguez-Gutiérrez; Rafael Bohollo-de-Austria; Ángel Estella; Pilar Martínez-García; María Ángela González-García; Jordi Rello
Journal:  J Pers Med       Date:  2022-01-10

9.  [Hemophagocytic lymphohistiocytosis in critically ill patients].

Authors:  Dennis A Eichenauer; Gunnar Lachmann; Paul La Rosée
Journal:  Wien Klin Mag       Date:  2021-10-21

10.  Association of Hyperferritinemia With Distinct Host Response Aberrations in Patients With Community-Acquired Pneumonia.

Authors:  Xanthe Brands; Tjitske S R van Engelen; Floris M C de Vries; Bastiaan W Haak; Augustijn M Klarenbeek; Maadrika M N P Kanglie; Inge A H van den Berk; Alex R Schuurman; Hessel Peters-Sengers; Natasja A Otto; Daniël R Faber; René Lutter; Brendon P Scicluna; Jaap Stoker; Jan M Prins; W Joost Wiersinga; Tom van der Poll
Journal:  J Infect Dis       Date:  2022-06-01       Impact factor: 7.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.